Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
nice volume lately, its getting primed! I bought a few shares Tuesday and today!
Lets Go PPCB! We need another run!
My take is they have no special sauce…only dilution.
More dilution, nice the executives enjoy "fat cat" salaries and trips to expensive trade shows wining and dinning on shareholders monies. Maybe they should cut their salaries to zero until they produce something of value for their shareholders, doubtful b/c they'll just milk this for as long as people buy into their narrative that the company has a "special sauce" worth billions.
~ 47 million shares added to the Outstanding Share Count since 3-9-2024:
No kidding. Everyone sold bc they gave out no new information.
More like a ball buster
I will hold until Friday. Lack of info is not interesting. Pump and dump!😒
The call was so amateurish. On top of the pisspoor audio quality, they could not even agree on the way forward. The German doc seemed to be on another wavelength than the others. Anyway, any result is still two years away at minimum, once toxicity tests, dosage issues are completed. CEO will pocket another million or so in the process. Strange that the Spanish professor from Jaen all but disappered from the radar screens. She seemed the only one to understand what is going on (but that's perhaps why she jumped ship or was disposed of).
Anyway, zero hard data was provided as to PRP efficacy (no side effect but no life was saved either, just a way to prolong your miserable end of life and enjoy your cancer a bit longer)
Check this out..
This video was posted 3 weeks ago..
I saw it the day it came out... CEO talks about series A Financing...
the call is being hosted by Allele Capital and they have Nasdaq Companies and Private Companies on their "engagements" page. Allele Capital has raised money for a few of them. https://www.allelecapital.com/engagements
PPCB is the only OTC stock they have worked with (that I can see)!
“This is going to be a blockbuster”-
CSO Kenyon
Ceo is on right now.
5 panelist.
I freaking tried. The stupid ass “linked in” video doesn’t have any sound.
I’m so fking pissed.
Wait.. I think it’s finally working.
It’s on right now I’m watching.
Idk if this is live or a replay ?
did you listen to the call today? PPS is down and im wondering if any news from the call is the reason why.
$PPCB, It has potential to explode. imo.
This could hit pennyland big time if they let it run! I’d love to see it.
Float is only approximately 80 million from my estimation count of watching everyday since the latest ss update.
We’ll see…
Bottom line…
I think it’s worth a lot more than the current market cap. (2-300k?) that’s peanuts for a cancer stock with this type of TAM and potential market share.
I already did my research on this ticker. I know PRP has blockbuster potential.
Imo., PPCB could potentially have a good run this year.
Ooooof big shot of cannolis
Oh boy fluffy of buys maybe big news pre market
im watching.... I'm all-in on a different ticker so PPCB has been and is usually just a short hold for me.
Good Job!
I got .003 bidding low .003s
and I got out yesterday!!!! This is my luck with PPCB, I can never seem to catch a run!
Good Luck To You!
I’m in
$PPCB share structure + chart + catalyst… added .003 pic.twitter.com/jxXeSlwDFF
— TweetVestor3 (@TVestor3) March 27, 2024
is anyone gonna listen/watch the conference call that is gonna happen on Thursday?
Share Structure Updated, close to 20 million shares added;
Outstanding Shares: 72,101,012 03/09/2024
Restricted Shares: 727,859 03/09/2024
Unrestricted Shares: 71,373,153 03/09/2024
https://www.otcmarkets.com/stock/PPCB/security
No chance it holds…they are on the dilution juice. Your cash is their juice
Please don’t buy this fake public co
The ceo owns the only voting stock..
It’s like buying the US dollar.. it’s just going to be worth less
Well it stopped going down last week. Let’s see if the bottom holds…
Yeah I’ve done the research on their candidate and it looks like it could be a blockbuster if ever gone to market, but then being in Australia, never taking investor phone calls, never responding to emails, enacting reverse split after reverse split, delaying and postponing trials year after year, makes it all seem unbelievable at this point.
progress is very slow in the biopharma field... Ive been waiting for First in Human trials every year that may happen in the 2nd half of "next year" for the last 6 years at least!!!
I dont want to be left out if the trials ever start. I would rather lose money, I finally made money yesterday (overall a big loss though), then miss out on announcement of First in Human trials. That would be the game changer for PPCB (imo).
Good Luck To You!
It won’t be. These cats are living in luxury making empty promises and diluting to stay alive.
I’m intrigued by this as well. But we’ve watched for many years and they’ve always failed to come through on any promises. Why would this time be any different ?
What would be remarkable is no more reverse splits from these blood suckers
Why a conference call vs. a PR? Conference calls cheaper?
This is an outrage of an Iinveswnt!
Buy anything else.. anything you will lose less money
trust me ive been involved/watching PPCB for a long time. It does have its runs and ive missed out on all of them!
This is the first time ive seen "conference call" on any PR that I can remember from PPCB. Also on the PR it stated:
You are kidding, right? March 28? Sure it is 2024? It takes them as much time to organize a conterence call as it does to postpone FIH trials tome after time. Zero credibility into what they will tell, they will NEVER survive as long as the CEO rewards homself with 450000 dollars a year
News!!! Conference Call on March 28th on the compassionate use study results!!! https://www.otcmarkets.com/stock/PPCB/news/story?e&id=2774171
on a side note, Share structure updated approximately 13 million shares added to O/S from January 9th to February 9th:
Outstanding Shares: 52,144,948 02/09/2024
Restricted Shares: 727,859 02/09/2024
Unrestricted Shares: 51,417,089 02/09/2024
Buying today, hopefully I can finally catch a run with PPCB!!!!!!
still controlled by the TROLLS
Please enlighten us on this reverse spitting POS...seems like just another reverse splitting POS that can't get off the dime and deliver anything of value...meanwhile cancer keeps winning. I'm down so much it's embarrassing and I've been here for 2 years, so don't resort to "jumping in and out of stocks". This thing will RS again as soon as they get back to the trips
Small cap discussion boards are really a wasteland. If you are angry because you’re not rich, if you hate the company and come up with perpetual reasons to post hateful and erroneous comments, if you’re not willing to invest and let it ride; if you’re just in and out of stocks at random on low information, . . . if you just cook up conspiratorial bullshit about how you’re being ripped off, then why are you even here? Go invest in Apple or Tesla and just sleep soundly.
Foundational Patent means an Excluded Intellectual Property that is a patent that has been adopted or will be adopted into a technical standard by an international or governmental authority or association.
Y’all need to educate yourselves — ‘foundation patent.’
Followers
|
407
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
48342
|
Created
|
05/18/14
|
Type
|
Free
|
Moderators |
This section maintained by INV4
Offering New Hope to Cancer Patients and Their Caregivers
About Propanc Biopharma, Inc. The Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes could represent the body’s primary defense against cancer. A Long-Term Therapy Based on a Pancreatic Proenzyme Formulation Developing Long-Term Therapy for the Treatment of Solid Tumors Technology Based on Pancreatic Proenzyme Therapy Treatments that Inhibit Tumor Growth and Metastasis Our Lead Product: PRP Technology Based on Pancreatic Enzyme Therapy More than one hundred years ago, Professor John Beard first proposed that the pancreatic enzymes represent the body’s primary defense against cancer and would be useful as a cancer treatment. Since then, several scientists have endorsed Beard´s hypothesis with encouraging data from patient treatment. |
Click here for the video (with sound)
====================== PPCB SECURITY DETAILS ======================
Share Structure
Market Cap | 1,652,679 | 02/27/2023
Authorized Shares | 10,000,000,000 | 02/13/2023
Outstanding Shares | 1,836,310,391 | 02/13/2023
Restricted | 194,354,827 | 02/13/2023
Unrestricted | 1,641,955,564 | 02/13/2023
Held at DTC | 1,641,916,456 | 02/13/2023
Board of Directors James Nathanielsz has served as a director and Chief Executive Officer of our company since October 2007. From July 2006 until October 2007, Mr. Nathanielsz served as the New Products Manager of Biota Holdings Limited, an anti-infective drug development company in Australia. Mr. Nathanielsz was selected as a director because he is the Co-Founder of Propanc and for his experience in R&D and manufacturing and distribution. Mr. Nathanielsz holds a B.App.Sci in Biochemistry/Applied Chemistry and an M.E.I. from Swinburne University of Technology in Melbourne, Australia. ============== Dr. Julian Kenyon founded our company and was appointed as a director on February 12, 2008. Since 2000, Dr. Kenyon has served as an integrated medical physician and Medical Director of the Dove Clinic for Integrated Medicine in Winchester and London. He was the Founder-Chairman of the British Medical Acupuncture Society in 1980 and Co-Founder of the Centre for the Study of Complementary Medicine in Southampton and London. Dr. Kenyon was selected as a director because he is the Co-Founder of the Australian subsidiary and the business is based on his initial work at the Dove Clinic. Dr. Kenyon holds an M.B.Ch.B. and M.D. from the University of Liverpool Since 1972, he was appointed a Primary Fellow of the Royal College of Surgeons, Edinburgh. ============== Mr Zelinger is a Certified Practicing Accountant with 45 years of experience in tax, auditing, finance, investment and management consulting. Mr Zelinger also has significant expertise in property management and import/export businesses. Mr Zelinger commenced his career as an accountant at L.M. Stanton & Partners - Chartered Accountants, subsequently joining Caston Pty Ltd in 1980, a steel manufacturer as Chief Financial Officer, and Company Director, until 1983. Since the mid-1980’s until current date, Mr Zelinger serves as Director in several private investment companies in a range of businesses including property portfolio manager of commercial real estate, import/export businesses and a range of commercial and financial investment companies. Since 1980, Mr Zelinger also operates as a sole practitioner in accountancy and tax consulting. In 1973, Mr Zelinger graduated in Accounting and admitted as a Fellow of RMIT University in Business. He has been a Certified Practicing Accountant since 1984. Mr. Zelinger is a shareholder of Propanc Biopharma Inc. since 2010. ======================================================================== Company Info Industry Classifications |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |